Liquid Colchicine Formulation for Stable Drug Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Colchicine solutions for oral administration have been unstable and prone to degradation, and existing formulations result in significant adverse events, limiting their use and effectiveness.
Innovation Solution
Development of a stable liquid colchicine oral solution that maintains consistent blood levels and reduces adverse events when co-administered with various drugs, including P-gp and CYP3A4 inhibitors, while providing a safer alternative to traditional tablets or capsules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If colchicine is formulated as a liquid oral solution, then ease of administration and patient compliance are improved, but stability and degradation resistance deteriorate
Solution Approach 1:
The patent introduces a stabilizing agent as an intermediary substance in the liquid formulation that mediates between the colchicine and the aqueous environment, preventing degradation while maintaining solubility and liquid state for easy administration
Solution Approach 2:
The patent creates a composite liquid formulation combining colchicine with specific excipients, stabilizing agents, and pH adjusters to achieve both liquid state for ease of administration and enhanced stability through synergistic interactions among components
2Reliability
If colchicine is administered with P-gp inhibitors, then therapeutic effectiveness is improved, but adverse events increase
Solution Approach 1:
The patent applies a lower colchicine dose (0.3-0.6 mg) when co-administered with P-gp inhibitors, using partial action to achieve therapeutic effectiveness while avoiding excessive accumulation that causes adverse events
Solution Approach 2:
The patent implements monitoring of colchicine blood levels with feedback-guided dose adjustment when patients are co-administered with P-gp inhibitors, allowing therapeutic effectiveness while preventing adverse events through dynamic dose optimization
3Reliability
If colchicine is administered with strong CYP3A4 inhibitors, then therapeutic effectiveness is improved, but colchicine blood levels increase significantly
Solution Approach 1:
The patent reduces colchicine dose to 0.3 mg when co-administered with strong CYP3A4 inhibitors like posaconazole, using partial action to maintain therapeutic effectiveness while preventing excessive blood level accumulation
Solution Approach 2:
The patent provides beforehand cushioning by pre-establishing dose reduction protocols and monitoring plans before patients are co-administered with strong CYP3A4 inhibitors, preventing excessive colchicine accumulation before it occurs
Data Source
AI summary
The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.